New chemistry reduces barriers to scaling single-cell studies across research settingsLaunch planned for March 2026, available across Evercode Whole Transcriptome product lineSEATTLE, Wash. & VENLO, ...

ArgenTag joins PacBio to enable instrument-free single-cell kits to support long-read isoform sequencing at single-cell ...

Tempus AI TEM rose on Wednesday after the company unveiled its new HRD-RNA algorithm, an AI-driven tool designed to improve detection of homologous recombination deficiency (HRD) in tumors. The ...

Tempus HRD-RNA is an AI-driven, 1,660-gene logistic regression model designed to identify patients likely to respond to ...

Investing.com -- Tempus AI, Inc. (NASDAQ:TEM) stock rose 3.5% Wednesday after the precision medicine technology company announced the launch of its new HRD-RNA algorithm for cancer detection.

In a new study, an aging clock has revealed neuron-specific aging, as well as potentially neuroprotective compounds.

With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology advances.

This study reports an important and novel finding that TENT5A, an enzyme involved in fine-tuning poly(A) tail length on selected mRNAs, is required for proper enamel mineralization in mice. The ...

From molecular chaperones to mitochondrial failure, discover how heat reshapes the human transcriptome and drives the biological cascade that links rising temperatures to organ injury and public ...

Tempus AI Inc. TEM shares are up on Thursday as Mizuho initiated coverage on the health care-focused artificial intelligence firm. Analyst Bradley Bowers started coverage with an Outperform rating and ...

Department of Chemistry and Biochemistry, University of South Carolina, Columbia, United States ...

Single-cell science is rapidly evolving beyond "one-shot" compartment chemistry. Atrandi's SPC technology was built for ...